Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18967972 | 0.99 | P2RX7 (0.34) | PRMT3P2RX7HRH3TP53SMN1; SMN2 | |
| SCHEMBL18939046 | 0.91 | KDR (0.38) | PRMT3P2RX7HRH3 | |
| SCHEMBL18939006 | 0.83 | PLAU (0.42) | HTR6 | |
| SCHEMBL18967594 | 0.82 | PRMT3 (0.34) | PRMT3P2RX7TP53SMN1; SMN2POLB | |
| SCHEMBL18967700 | 0.80 | HRH3 (0.35) | PRMT3P2RX7HRH3TP53SMN1; SMN2 | |
| SCHEMBL18960808 | 0.80 | NR3C1 (0.36) | HTR6 | |
| Hydrochloric Acid SCHEMBL18938987 | 0.79 | NR3C1 (0.36) | HTR6 | |
| SCHEMBL18967767 | 0.79 | P2RX7 (0.34) | PRMT3P2RX7HRH3HTR6 | |
| SCHEMBL18952021 | 0.77 | SLC22A12 (0.35) | P2RX7HTR6 | |
| Hydrochloric Acid SCHEMBL28662896 | 0.77 | FLT1 (0.39) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | CEP170, AADAC, NAA50 | PRMT3 56/4885P2RX7 2529/4885HRH3 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.